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OBJECTIVE—Autoimmune target tissues in type 1 diabetes
include pancreatic -cells and peri-islet Schwann cells (pSC)—
the latter active participants or passive bystanders in pre-diabetic
autoimmune progression. To distinguish between these alterna-
tives, we sought to suppress pSC autoimmunity by transgenic
expression of the negative costimulatory molecule B7-H1 in NOD
pSC.
RESEARCH DESIGN AND METHODS—A B7-H1 transgene
was placed under control of the glial ﬁbrillary acidic protein
(GFAP) promoter. Transgenic and wild-type NOD mice were
compared for transgene PD-1 afﬁnities, diabetes development,
insulitis, and pSC survival. Mechanistic studies included adoptive
type 1 diabetes transfer, B7-H1 blockade, and T-cell autoreactiv-
ity and sublineage distribution.
RESULTS—Transgenic and endogenous B7-H1 bound PD-1 with
equal afﬁnities. Unexpectedly, the transgene generated islet-
selective CD8
 bias with accelerated rather than suppressed
diabetes progression. T-cells of diabetic transgenics transferred
type 1 diabetes faster. There were no earlier pSC losses due to
conceivable transgene toxicity, but transgenic pSC loss was
enhanced by 8 weeks, preceded by elevated GFAP autoreactivity,
with high-afﬁnity T-cells targeting the major NOD K
d-GFAP
epitope, p253–261. FoxP3
 regulatory T- and CD11c
 dendritic
cell pools were unaffected.
CONCLUSIONS—In contrast with transgenic B7-H1 in NOD
mouse -cells, transgenic B7-H1 in pSC promotes rather than
protects from type 1 diabetes. Here, ectopic B7-H1 enhanced the
pathogenicity of effector T-cells, demonstrating that pSC can
actively impact diabetes progression—likely through modiﬁca-
tion of intraislet T-cell selection. Although pSC cells emerge as a
new candidate for therapeutic targets, caution is warranted with
regard to the B7-H1–PD1 axis, where B7-H1 overexpression can
lead to accelerated autoimmune disease. Diabetes 59:2588–
2596, 2010
T
he NOD mouse is a spontaneous model of type
1 diabetes, with genetic and pathophysiologi-
cal roots comparable with the human disease
(1). Pancreatic islets of Langerhans are tightly
enveloped by peri-islet Schwann cells (pSC) that ex-
press glial ﬁbrillary acidic protein (GFAP), a marker of
Schwann cells and astrocytes (2). During pre-diabetes
progression, T-cell inﬁltrates accumulate at the endo-
crine/exocrine border, constituted by the pSC mantle,
where lengthy “peri”-insulitis lasts for weeks to months
in NOD mice and likely for years in humans with islet
autoimmunity. Eventual breakdown of the pSC mantle
initiates pathogenic islet invasion, progressive -cell
loss, insulin deﬁciency, and overt diabetes development.
In NOD mice, CD8
 T-cells predominate islet attack
until late in this process (3).
Islet T-cell inﬁltrations are heterogeneous in their
target autoantigen speciﬁcities for not only -cell–
selective autoantigens (e.g., insulin) but also autoanti-
gens shared by -cells and nervous system tissue,
islet-associated autoantigens shared by pSC and -cells
(e.g., S100) or those that are pSC speciﬁc (e.g., GFAP)
(4). pSC functions and their importance in type 1
diabetes development have yet to be fully characterized.
In NOD mice, pSC-speciﬁc T-cell autoreactivities are
present by 5 weeks of age. GFAP target epitopes were
recently mapped to residues 79–87 and 253–261 for K
d
and 96–110, 116–130, and 216–230 for NOD-IA
g7, and
fresh ex vivo CD8
 cells mediate direct lysis of primary
pSC cultures from diabetic NOD mice (5).
pSC cells likely have physiological functions similar
to conventional Schwann cells of the peripheral nervous
system, providing neurotrophic support for islet-inner-
vating neurons as well as the neural crest-derived -cell
(2). For example, nerve growth factor, glial cell—
derived neurotrophic factor, and insulin-like growth
factor-1 promote -cell survival and probably regenera-
tion (6–8). Loss of these factors with pSC destruction
may amplify -cell stress, enhancing -cell susceptibil-
ity to inﬂammatory insults (7). Anatomically, pSC pro-
vide a physical barrier to inﬁltrating T-cells,
accumulating at the endo-exocrine islet border and
impeding direct - and T-cell contact.
B7-H1, a ligand for programmed death (PD)-1, is ex-
pressed by CD4
 and CD8
 T-cells, B-cells, dendritic cells
(DCs), macrophages, mast cells, and nonhemopoietic
tissues (9). In nonlymphoid tissue, DC-B7-H1 supports
peripheral tolerance, limiting randomly arising autoag-
gressive lymphocytes and their inﬂammatory tissue dam-
age (10,11). In tumors, expression of B7-H1 contributes to
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speciﬁc T-cells (12–14). Consistently with an inhibitory
role, treatment of NOD mice with blocking antibodies to
either PD-1 or B7-H1 accelerates diabetes (15), with anal-
ogous scenarios in autoimmune (16) and other (12,17,18)
models. These systemic manipulations of the PD-1/B7-H1
axis generated the consensus view that B7-H1 ligation
keeps potentially damaging autoimmune T-cells in check
and serves to downregulate lymphoid effector functions
(19).
However, conﬂicting data exist. The B7-H1 pathway
can promote T-cell activation and autoimmunity in
certain experimental settings, including transgenic ex-
pression of B7-H1 in -cells of C57Bl/six mice (20–22).
For these exceptions, an alternative receptor for B7-H1
has been proposed but not identiﬁed to date (23,24). We
nevertheless felt that the weight of evidence, speciﬁ-
cally in NOD mice, suggested that B7-H1 might serve as
a tool to selectively suppress NOD pSC autoimmunity,
allowing us to learn whether and how pSC cells impact
on the -cell autoimmune progression program: trans-
genic expression of B7-H1 in NOD -cells protects from
type 1 diabetes (19). We here describe the effects of a
pSC B7-H1 transgene. Our ﬁnding of type 1 diabetes
acceleration emphasizes the complexity of this costimu-
latory pathway, while the selective, intraislet CD8
 bias
of high-afﬁnity T-cells demonstrates that pSC cells do
impact the -cell destruction program, culminating in
type 1 diabetes.
RESEARCH DESIGN AND METHODS
GFAP promoter–driven transgenic NOD mice. B7-H1 cDNA was derived
by RT-PCR from NOD mouse splenocyte RNA and inserted into a GFAP
expression cassette (Fig. 1A) (25). This construct was injected into fertilized
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FIG. 1. B7–H1 transgene construct and expression. A: Construct map with GFAP promoter (GFAPp), restriction sites, and poly-A region (gray).
B: Transgene-speciﬁc RT-PCR (see RESEARCH DESIGN AND METHODS) in various tissues. Lower lane: cDNA calibration controls (glucuronidase).
B7–H1 transcripts were detectable in brain, sciatic nerve, puriﬁed and cultured pSC, colon, and salivary gland. C and D: Confocal ﬂuorescent
microscopy of wild-type NOD (C) and GFAP-tg (D) pancreas sections stained for insulin (blue), GFAP (green), and B7–H1 (red). pSC expression
of B7–H1 was only detected in transgenics, coexpressed with GFAP (yellow). E and F: B7–H1 protein expression (green) was abundant in
transgenic brain tissue (E), with only weak autoﬂuorescence in brain tissue edges of wild-type (wt) controls (F). G: Biacore analysis of
transgenic (left panel) vs. endogenous B7–H1 wild type (right panel) revealed near-identical afﬁnities with the PD-1 receptor (G) (Table 1). (A
high-quality digital representation of this ﬁgure is available in the online issue.)
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diabetes.diabetesjournals.org DIABETES, VOL. 59, OCTOBER 2010 2589NOD ova, generating two independent male founders. One died young, with
typical overt type 1 diabetes, before successful breeding. Positional cloning
and sequencing indicated that the surviving founder carried the transgene on
chromosome 12 (chr12:3302043.0.3202044, Mus musculus, build 37.1) in a
noncoding region, not near known NOD type 1 diabetes risk loci. This founder
and offspring developed and bred normally but had an immune phenotype (see
below). NOD, NOD.scid, NOD-derived GFAP promoter–driven transgenic
(GFAP-tg), and GFAP-tg.scid mice were generated and maintained under
approved protocols in our vivarium. GFAP-tg.scid resembled NOD.scid in
every respect, including normal pancreas histology and confocal
immunoﬂuorescence.
Surface plasmon resonance analysis. NOD B7-H1, from transgenic brain,
or wild-type spleen were puriﬁed with a B7-H1 antibody (Cedarlane, Bulling-
ton, ON, Canada), coupled to an afﬁnity column (GE Healthcare, Mississauga,
ON, Canada). A CM5 Biacore chip was used to couple 200 response units of
PD-1 (R&D Systems, Minneapolis, MN), and serial dilutions of puriﬁed B7-H1
(4.25–100 nmol/l) were injected. BIAevaluation software was used for
analysis.
Histobiochemistry and image analyses. For insulitis quantitation, frozen
tissue was processed, hemotoxilin-eosin–stained, and scored as previously
described (4). Three-color immunoﬂuorescence was used for confocal
imaging of GFAP (in pSC and astrocytes), CD3, and insulin as previously
described (4). For GFAP quantiﬁcation studies, Volocity software was
used; 68–100 islets/group were counted. Each individual islet perimeter
was identiﬁed through islet autoﬂuorescence and traced, and the total islet
area was calculated (micrometers squared). The GFAP staining signal
(ﬂuoroisothiocyanate) of pSC was quantiﬁed within each islet by selective
identiﬁcation of “green” pSC and calculated as a percentage of GFAP-
positive staining (in pixels) per total area of each islet, measured in
micrometers squared. Image-J software was used to image the steric
distribution of pSC loss, comparing GFAP green pixel counts in wild-type
and transgenic islets of 8-week-old mice.
Cell preparations and transfers and in vitro studies. Spleen cells were
prepared for intravenous injection or for in vitro cultures as previously
described (4). Splenocytes (10
7) from NOD females with recent diabetes onset
were injected intravenously into 8-week-old NOD.scid or GFAP-tg.scid recip-
ients either treated or untreated with 200 g i.p. mouse anti–B7-H1 antibody
(R&D Systems) every second day. T-cell proliferation assays of splenocytes
from 5- to 13-week-old NOD females were completed and analyzed as
previously described (26). For DC antigen presentation analysis, 2  10
4
CD11c
 GFAP-tg or wild-type NOD DCs were puriﬁed with a CD11c

selection kit (Stem Cell Technologies, Vancouver, BC, Canada) from spleens
and cocultured with 2  10
5 T-cells puriﬁed with a CD3
 selection kit (Stem
Cell Technologies) from 10-week-old wild-type NOD mice and pulsed with
insulin. For pancreatic lymph node T-cell proliferation assays, 2  10
5
lymphocytes from wild-type NOD or GFAP-tg animals were seeded with 2 
10
5 irradiated splenocytes, pulsed with GFAP, processed, and analyzed as
previously described (2).
T-cell and DC Studies. Pancreata were digested with collagenase (20/
37°C), dissociated, and applied to a Ficoll gradient. Islets were hand-
picked and cultured in leukocyte complete medium with 18 ng/ml
interleukin-2 for 8 days prior to staining (5). Cells were stained for ﬂow
cytometry with anti-CD8 or anti-CD11c, CD11b, and/or B7-H1 and gated as
indicated (e.g., CD3
).
Diabetes monitoring. Blood glucose was measured twice weekly in animals
8 weeks old; measurements 13.8 mmol/l in two consecutive readings were
considered diabetic. Insulin and glucose sensitivity and tolerance were
measured as described (2).
Sialitis. hemotoxilin-eosin–stained submandibular salivary glands were
scored by two blinded observers. Mononuclear foci were scored as “small” at
75 inﬂammatory cells/section and “large” at 75 inﬂammatory cells/section.
RESULTS
Characteristics of B7-H1 transgenic mice. B7-H1 ex-
pression was detected by transgene-speciﬁc RT-PCR in
neuronal tissues, including brain and sciatic nerve, in
pancreas but not in thymus or spleen (Fig. 1B). Traces of
transgene transcripts were also found in colon and sali-
vary glands. B7-H1 protein expression did not completely
correlate with transcription proﬁles, which is not uncom-
mon (27). Total B7-H1 protein expression was similar
in transgenic and age- and sex-matched wild-type mice in
most tissues examined but comparatively elevated in
transgenic pSC cells and brain (Fig. S1, available in an
online appendix at http://diabetes.diabetesjournals.org/
cgi/content/full/db09-1209/DC1). Confocal immunoﬂuores-
cence colocalized GFAP and B7-H1 to transgenic pSC
cells, with undetectable B7-H1 in wild-type pancreata (Fig.
1C and D). There was considerable transgene expression
throughout the central nervous system in transgenic but
not wild-type mice (Fig. 1E and F). Insular transgene
expression in pSC did not generate endocrine malfunction,
as analyzed by glucose and insulin sensitivity tests (Fig.
S2). Transgene protein expression in colon and salivaries
was at best very low and inconsistent in GFAP-tg mice
(Fig. S1).
We compared binding afﬁnities of puriﬁed wild-type
PD-1 to wild-type and transgenic B7-H1 by surface
plasmon resonance, with binding kinetics analyzed by
1:1 Langmuir binding isotherms (Fig. 1G; Table 1). No
differences were identiﬁed, suggesting that the trans-
gene ligates PD-1 normally. Collectively, these observa-
tions argue strongly that GFAP-tg phenotypes reﬂect
B7-H1 costimulatory function in the islet locale rather
than nonspeciﬁc transgenesis effects—a conclusion fur-
ther supported by in vivo B7-H1 blocking studies (dis-
cussed below).
Type 1 diabetes development in GFAP-tg. As shown in
Fig. 2A, transgenic mice progressed more rapidly to type 1
diabetes than wild-type females (P  0.0017, life tables).
More rapid pre-diabetes progression peaked by 19 weeks,
with two-thirds of GFAP-tg diabetic compared with one-
tenth of wild-type control mice. To begin exploring the
mechanism of this counterintuitive phenotype, we quanti-
ﬁed the progression of islet inﬂammation. The early phase
of islet inﬁltration (peri-insulitis) was unaffected in trans-
genics (P  0.1 vs. wild type) (Fig. 2B–D), but by 8 weeks
of age, insulitis was much enhanced (Fig. 2B) and was
more invasive in GFAP-tg mice compared with controls
(P  0.001) (Fig. 2C). Insulitis progression continued to
accelerate (Fig. 2C) up to overt diabetes declaration (P 
0.001) (Fig. 2D).
Enhanced pSC loss in GFAP-tg. To determine whether
increased insulitis severity correlated with accelerated
pSC loss, a quantitative scoring system was developed.
pSC integrity was measured as GFAP pixel-counts/islet
cross-section. There was marked variation of islet sizes,
but the distribution was similar in 8-week-old transgenic
and wild-type mice, wild-type and transgenic NOD.scid
mice, and 3-week-old wild-type or transgenic mice (P 
0.1) (Fig. 3A). However, the GFAP content (percentage of
area) was much reduced in 8-week-old transgenics (P 
0.0001) (Fig. 3B). This loss was autoimmune mediated,
given that GFAP-tg.scid (and very young animals) did not
have GFAP loss (P  0.1) (Fig. 3B). We used three-
dimensional imaging to map the spatial distribution of pSC
loss. As shown in Fig. 3C–E, transgenics clearly depleted
TABLE 1
Binding properties of B7-H1 and B7-H1 transgene (tg) to PD-1
receptor
Binding afﬁnity
Surface plasmon resonance
Kd
(nmol/l)
kon (10
4
mol  l
	1  sec
	1)
koff
(sec
	1)
Rmax
(RU)
B7-H1 3 PD-1 11 16.7 0.0017 39.5
B7-H1 tg 3 PD-1 11 15.8 0.0017 36.4
Kd, equilibrium dissociation constant; koff, dissociation constant; kon,
association constant; RU, resistance unit.
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was maintained in young (Fig. 3C) as well as 8-week-old
wild-type mice (Fig. 3D). Thus, several independent ap-
proaches, from histology to quantitative imaging, fully
supported each other, and the addition of wild-type and
transgenic NOD.scid mice added credibility to the notion
that the transgenic phenotype reﬂects pSC impact on
pre-diabetic autoimmunity.
Increased pathogenicity in GFAP-tg mice. Splenocytes
from diabetic GFAP-tg donors transferred diabetes to
wild-type NOD.scid recipients dramatically faster to more
recipients than did wild-type diabetic donor cells (P 
0.023) (Fig. 4A; life tables), demonstrating that the trans-
gene drives quantitative or qualitative immune changes
that enhance the pathogenicity of systemic immune cells.
Consistently, transfer of wild-type splenic grafts into trans-
genic NOD.scid recipients showed intermediate pathoge-
nicity, with similar penetrance but slower pace of type 1
diabetes development in transgenic NOD.scid recipients
(P  0.02). Thus, these transfer data support those from
natural history disease development (Fig. 2A), directly
demonstrating type 1 diabetes acceleration in and by the
transgenic islet.
The rapid adoptive transfer model facilitated studies of
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FIG. 2. Transgenic B7–H1 accelerates autoimmunity. A: Natural type 1 diabetes incidence in NOD females (wild-type [wt] NOD N  25;
GFAP-tg mice N  22 [P  0.006]). B: Histological analysis of wild-type and transgenic pancreata. Tissue was retrieved for immunohisto-
chemistry at the ages indicated and stained for insulin (blue), GFAP (green), and CD3 (red). C: The progression of insulitis is signiﬁcantly
accelerated (P  0.0001) in transgenics older than 4 weeks. **P < 0.001. D: Distribution of insulitis scores over time (N  8/group; P < 0.001
at 8 and 13 weeks). Scoring scale: 0 (blue), no insulitis; 1 (green), peri-insulitis; 2 (orange), 25–50% invasive islet damage; and 3 (red),
>50% islet mass destroyed. There were >200 islets counted/mouse pancreas. wk, week. (A high-quality digital representation of this ﬁgure
is available in the online issue.)
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mice. Systemic blockade of B7-H1 by antibodies mediated
acceleration and higher penetrance of type 1 diabetes
development (P  0.02) (Fig. 4B). In contrast, antibody
blockade had no effects on the enhanced pathogenicity of
transgenic grafts, indicating that the transferred pool of
cells was no longer B7-H1 dependent (P  0.1) (Fig. 4C).
These results indicate that transgenic pSC cells inﬂuence
local T-cells at the islet level, which are then recirculated
into systemic distribution, refractory to further B7-H1
signals. In transgenics, this change is associated with
cognate expansion of CD8
 effector T-cells (as discussed
below).
Enhanced T-cell selection in transgenic islets. To
better understand the enhanced pathogenicity of autore-
active T-cell pools in transgenics, we compared in vitro
proliferative recall responses to GFAP (pSC-cell speciﬁc)
and insulin (-cell speciﬁc; B9–23) (Fig. 5). T-cell reactiv-
ity to both autoantigens was observed in transgenic and
wild-type mice. While insulin autoimmunity ampliﬁed,
with pre-diabetes progression in both groups equally,
transgenic GFAP recall responses peaked early and then
declined and in fact differed signiﬁcantly at every time
point measured, with the decline in transgenics a good
correlate of earlier pSC demise (Fig. 3E). Similarly, GFAP
responses to the main NOD target epitope, GFAP p253–
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concentrations, suggesting cognate selection of high-afﬁn-
ity T-cell receptors—again consistent with the more mas-
sive, early pSC damage (0.1 g/ml, P  0.020; 0.5 g/ml,
P  0.015) (Fig. 5C). These observations suggest that the
pSC transgene enhances the effectiveness of progressive
pSC damage through more effective pSC-speciﬁc T-cell
selection.
These data prompted us to compare T sublineage dis-
tribution in transgenic and wild-type mice. The different
pre-diabetic tissues analyzed had similar numeric and
proportionate T sublineage distributions in both mouse
lines (Fig. 6A and B). However, a striking, transgene-
driven phenotype was the islet-exclusive expansion of the
proportions (P  0.05) (Fig. 6C) and numbers of CD8

intraislet T-cell pool (P  0.002). This independently
supports the above conclusion that the pSC transgene
imparts more pathogenic T-cell selection. There were no
other changes in the cellular distributions, including B7-
H1
 dendritic cells (Fig. S3).
No transgene effects in early pre-diabetes. Autoim-
mune priming of (ultimately) pathogenic T-cells is thought
to occur at a young age in pancreatic lymph nodes, where
dendritic cells present fragments of apoptotic -cell debris
(28). There was not any evidence for more pronounced
pSC cell (or -cell) death in 3-week-old transgenic versus
wild-type mice (Fig. 7A and B), with terminal deoxynu-
cleotidyl transferase–mediated dUTP nick-end labeling–
stained thymus tissue serving as a positive apoptosis
control tissue (Fig. 7C). Absent GFAP-speciﬁc T-cell re-
sponses in pancreatic lymph node cells of the same
animals provided a functional read-out for autoantigen
unavailability at that time (Fig. 7D).
Early stages of the pre-diabetes progression program
in these NOD females were thus not affected by the
transgene, and enhanced number and pathogenicity of
local autoreactive T-cells in transgenics likely reﬂected
the local impact of positive costimulation by transgenic
B7-H1. To rule out a dysfunction of DCs in this process,
we puriﬁed DCs from transgenic and wild-type donors 3
weeks of age and used them to present antigen (insulin)
to puriﬁed pre-diabetic (10 weeks old) wild-type T-cells
(Fig. 7E). As shown, DCs from transgenic and wild-
type donors performed as well as antigen-presenting
cells.
The pSC transgene phenotype is pancreas selective.
The NOD mouse develops two genetically independent,
penetrant autoimmune disorders: type 1 diabetes and a
primary Sjo ¨gren syndrome (29). Only if the transgene
phenotype exclusively involved local costimulation in the
islet would we expect the “the other autoimmune disease”
(sialitis) to be unaffected. As shown in Fig. S4, sialitis
proceeded at similar rates and with similar features in
wild-type and GFAP-tg mice.
DISCUSSION
Systemic models (blocking or gene deletion) for the study
of PD-1 and its ligand, B7-H1, have unequivocally shown
dramatic effects on T-cell development (30–33), activation
in lymphoid tissue (34,35), and modiﬁcation of effector and
regulatory T-cell functions in various tissue sites (36,37).
With very few exceptions (20), PD-1 ligation is associated
with negative costimulatory function, and an elusive,
alternative B7-H1 receptor has been proposed, but not
identiﬁed, for the exceptions (23,24). We sought to employ
the negative costimulatory activity of B7-H1 to protect pSC
cells from autoimmune destruction and thus obtain a tool
to understand the pSC role in pre-diabetes progression.
This failed because B7-H1 transgenic pSC accelerated
disease development through selection of CD8
-biased,
more pathogenic, islet-resident T-cell pools. Our observa-
tions were more surprising because overexpression of
B7-H1 in -cells protected NOD mice from diabetes (19).
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FIG. 4. Enhanced pathogenicity of GFAP-tg T-cells. A: Reciprocal
adoptive transfers; injection of 15  10
6 splenocytes from diabetic
donors into wild-type (wt) or transgenic (Tg) NOD.scid recipients as
indicated in the ﬁgure (life table P values vs. wild type into wild-type
NOD.scid: 0.031 for transgenic splenocytes into wild-type NOD.scid and
0.023 for wild-type into transgenic recipients). B and C: Similar
adoptive transfers, adding animals receiving blocking doses of anti–
B7–H1 antibody (Ab) on day 0 and every 2nd day of study. B: Antibody
treatment accelerated type 1 diabetes development in wild-type recip-
ients of wild-type splenocytes (P  0.02). C: Anti–B7–H1 does not
affect pathogenicity of Tg splenocytes in wild-type recipients (P > 0.1).
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resistant C57BL/6 mice did generate diabetic mice (20).
Current information is insufﬁcient to explain these ﬁnd-
ings, but at the very least, one must conclude that expres-
sion of B7-H1 in nonhemopoietic tissue can bias local
immune regulation and effector function either positively
or negatively.
Irrespective of the molecular mechanisms that deter-
mine the outcome of tissue PD-1 ligation, our ﬁndings
demonstrate an immunologically meaningful, disease-rel-
evant interaction between T-cells and pSC cells in pre-
diabetes. In GFAP-tg animals, severe pSC depletion by 8
weeks is the harbinger of rapid -cell insufﬁciency. The
selective numerical and proportionate expansion of CD8

T-cells was exclusive to the islet locale, which is in line
with the lack of major histocompatibility complex class II
expression in pSC. The early peak of high-afﬁnity, pSC-
speciﬁc T-cell autoreactivity indicates that cognate events
drive this T-cell expansion. Without concomitant rises in
regulatory T-cells, these data delineate a cogent mecha-
nism for type 1 diabetes acceleration, supported by the
sharing of type 1 diabetes–associated target autoantigens
in pSC and -cells (2,4).
The enhanced pathogenicity at type 1 diabetes onset,
observed in adoptive transfer experiments, is then ex-
plained by systemic recirculation of the small islet T-cell
pools. In vivo B7-H1 blocking studies suggested that these
recirculated cells themselves are no longer inﬂuenced by
B7-H1. This might actually contribute to their pathogenic-
ity given that endogenous, negatively costimulating B7-H1
otherwise should have lessened the pathogenicity of these
T-cells.
Other contributors to rapid -cell loss likely include
depletion of pSC neurotropic factors, a long-recognized
pSC cell function (6–8). Thus, when transgenic and wild-
type islets were compared, our data demonstrated that
pSC actively modiﬁed the type 1 diabetes progression
program—in the present case through the selection of
more pathogenic anti-pSC T-cell reactivities.
One concern with any transgenic model is the creation
or modiﬁcation of a phenotype through insertional toxic-
ity, postcloning transgene rearrangements, or nonphysi-
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FIG. 5. Transgene effects on immune parameters. A–C: T-cell proliferation (N  5 mice/group). A: Splenocytes (4  10
5/well) of wild-type (wt)
or transgenic (tg) NOD mice aged 5–13 weeks (wk) were stimulated with whole GFAP, insulin peptide b9-23, or ovalbumin (ova). ConA,
Concannavalin A. B: Time courses of GFAP (left panel) but not of insulin responses (right panel) differ between wild-type and transgenic mice
(P  0.002, ANOVA). C: Enhanced high-afﬁnity T-cell responses to low concentrations of the major NOD GFAP peptide, p253–261, in wild-type
(black bars) and 5-week-old transgenic (red bars) mice (*P < 0.020). SI, stimulation index (mean counts/minute unstimulated/stimulated).
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possibility that the transgenic B7-H1 induced pSC apopto-
sis or affected islet physiology independently of T-cells,
the transgene was crossed to lymphocyte-deﬁcient NOD.
scid mice. On the scid background, spontaneous diabetes
was not observed and islets were indistinguishable from
NOD.scid controls. In addition, the transgenic phenotype
was faithfully transmitted in adoptive transfer studies,
indicating its immune nature. Thus, the present observa-
tions establish that pSC cell–T-cell interactions directly
impact diabetogenesis.
Rapid disease development in GFAP-tg mice reﬂects
the selection of more pathogenic T-cell pools, skewed
toward CD8
 T-cells. Regulatory T-cells have been
described to express the receptor for B7-H1 and PD-1
(37–39) and might be affected by the transgene ex-
pressed in the islet. However, the cellularity of
CD4
CD25
FoxP3
 T regulatory cells in GFAP-tg mice
was not different by total numbers or proportions.
Because of the very small absolute T regulatory num-
bers in the islet, we cannot exclude the possibility
that they might be functionally suppressed by the islet
transgene. This would then imply a coincidence of
positive and negative costimulation in the same
locale.
Collectively, the data now available cohesively sup-
port the conclusion that pSC cells are potent modula-
tors of islet inﬂammation, able to shape the pre-diabetes
progression program. Therapies that halt pSC damage
should delay or reduce -cell destruction, and innova-
tive strategies for islet transplants, local -cell regener-
ation, or de novo growth may beneﬁt from the
provision of pSC cell cografts derived from sural nerve
fragments.
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